Biogazelle offering services to support COVID-19 vaccine & therapeutics development

on May 12, 2020

Biogazelle has announced today that it has started supporting COVID-19 vaccine and therapeutics development by offering:

  • GCLP-compliant, high-throughput diagnostic testing of SARS-CoV-2 in an ISO17025 environment
  • Absolute quantification of viral load through digital PCR
  • High-throughput RNA expression profiling of therapeutic candidates to elucidate effects on cellular pathways and provide insights on potential toxicity
  • RNA biomarker analysis in clinical samples

    “In the last few weeks we have tested and validated a RT-qPCR workflow for high-throughput SARS-CoV-2 testing and acquired significant automation capabilities" said Mieke van Acker, CEO of Biogazelle. “By virtue of the experience we have acquired with patient sample testing, we are now able to offer this service to our industry partners while maintaining our unwavering commitment towards public health.”